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plasma,	 due	 to	 different	 causes	 such	 as	 the	 increased	 proteolytic	
degradation	of	VWF,	its	adsorption	onto	malignant	cells	or	activated	




secondary	 to	 systemic	 lupus	erythematosus	 (SLE)	was	 reported	by	
Simone	et al3	 in	1968.	Although	this	association	 is	 infrequently	de‐
scribed	 in	 literature,1,3,4	 even	 less	 frequent	 is	 its	presentation	with	
clinical	 and	 laboratory	 features	 resembling	 a	 severe	 VWD	 pheno‐
type.5	Most	 cases	 have	mild	 to	moderate	 bleeding	 tendency,	with	
laboratory	characteristics	similar	to	inherited	VWD	type	1.1,6,7
The	differential	 diagnosis	 between	AVWS	and	VWD	might	 be	
difficult	because	the	personal	history	of	bleeding	(acquired	or	 life‐
long)	 is	 not	 always	 conclusive	 and	 the	 two	 diseases	 share	 similar	
laboratory	 results.	 A	 potential	 diagnostic	 biomarker,	 the	 ratio	 of	
the	VWF	propeptide	(VWFpp)	to	VWF	antigen	(VWF:Ag)	(VWFpp/











showed	 a	 prolonged	 activated	partial	 thromboplastin	 time	 (aPTT),	
with	 a	 ratio	 of	 1.51	 (normal	 range	 0.86‐1.20).	 Haemoglobin	 was	





and	 heavy	 menstrual	 bleeding,	 but	 she	 had	 no	 lifelong	 personal	
and	family	history	of	bleeding.	The	laboratory	assessment	revealed	
a	pattern	resembling	a	severe	form	of	VWD,	with	very	low	plasma	
values	 of	 factor	VIII	 (FVIII),	 VWF:Ag,	VWF	 ristocetin	 cofactor	 ac‐
tivity	 (VWF:RCo)	 (Table	1,	Baseline)	 and	a	barely	detectable	VWF	
multimeric	 pattern.	 The	 tests	 for	 hepatitis	 C	 and	 B	 viruses	 were	
negative.	 Since	 the	 patient	 reported	 a	 significant	 bleeding	 history	
only	in	recent	times,	an	AVWS	was	hypothesized	and	the	laboratory	
evaluation	was	guided	by	this	hypothesis.	At	baseline	the	VWFpp/
VWF:Ag	 was	 54	 (normal	 range	 0.6‐1.6),	 indicating	 a	 normal	 pro‐
VWF	synthesis	but	 a	markedly	 increased	plasma	clearance	of	 this	
moiety,	as	typical	of	AVWS.	Mixing	test	with	the	Bethesda	method,	
using	 the	VWF:RCo	and	VWF:CB	assays,	 showed	 the	presence	of	
a	 mild	 inhibitor	 against	 VWF:RCo	 (1	 BU).The	 syndrome	was	 con‐
firmed	 by	 the	 normal	 intraplatelet	 VWF	 content,	 but	 the	 ELISA	
for	anti‐VWF	antibodies	demonstrated	a	high	titre	of	 IgG	and	also	
the	 presence	 of	 IgM	 (Table	 1).	 Further	 laboratory	 investigations	















complement	 fraction	 and	 beta2‐microglobulin	 became	 normal.	 A	
possible	explanation	of	an	AVWS	secondary	to	SLE	is	the	increased	
VWF	clearance	due	to	an	anti‐VWF	antibody.	The	enhanced	VWF	
clearance	 in	our	patient	was	confirmed	by	 the	markedly	 increased	
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immunosuppression	 therapy	 is	 critical	 for	 the	 treatment	of	under‐
lying	autoimmune	disorders,1	as	confirmed	herewith.	In	this	patient	














symposia	 and	 educational	 meetings	 organized	 by	 Ablynx,	 Grifols,	
Sobi,	Shire,	F.	Hoffmann‐La	Roche	and	Alnylam.	She	is	recipient	of	








lected	 clinical	 data.	 EB	 and	 FP	 discussed	 the	 results	 and	 critically	
revised	the	manuscript.
ORCID
Francesca Stufano  http://orcid.org/0000‐0001‐5214‐0580 








1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and 
Fondazione Luigi Villa, Fondazione IRCCS Ca’ Granda Ospedale 
Maggiore Policlinico, Milan, Italy
2Department of Pathophysiology and Transplantation, Università degli 
Studi di Milano, Milan, Italy
Correspondence
Flora Peyvandi, Angelo Bianchi Bonomi Hemophilia and Thrombosis 
Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Milan, Italy.
Email: flora.peyvandi@unimi.it
R E FE R E N C E S
	 1.	 Franchini	M,	Lippi	G.	Favaloro	EJ.	Advances	in	hematology.	Etiology	
and	 diagnosis	 of	 acquired	 von	 Willebrand	 syndrome.	 Clin Adv 
Hematol Oncol.	2010;8:20‐24.
	 2.	 Federici	AB,	Rand	JH,	Bucciarelli	P	et	al.	Acquired	von	Willebrand	





syndrome	 in	 systemic	 lupus	 erythematosus.	 Case Rep Hematol. 
2014;2014:208597.
TA B L E  1  Laboratory	assessment






Baseline 3 2 0.5b <1 54 1:640 1:40
50a 10 3 0.5b NT 60 1:1280 1:80
62 36 12 13 NT 9.4 1:640 1:20
78 149 73 71 73 2.05 1:160 1:20
125 190 123 122 161 1.17 1:40 <1:20
168 118 70 63 NT NT <1:20 <1:20
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Does haemophilia slow down the development of liver fibrosis?
Dear	Editor,












severe	consequences.	Until	 the	1989	discovery	of	HCV,3	 almost	 all	










philia	 HCV‐infected	 patients	 compared	 with	 HCV‐infected	 patients	






haemophilia	 A	 are	 currently	 available.	 These	 well‐characterized	






mice	 (=HEMO	mice)	with	 factor	 VIII	 levels	 <1%	 (7	weeks	 old;	 B6;	
129S‐F8tm1Kaz/J,	sourced	from	The	Jackson	Laboratory).	Each	group	
was	 divided	 into	 subgroups	 receiving	 either	 thioacetamide	 (TAA)	
in	their	drinking	water	(200	mg	TAA/L;	CTL‐TAA,	and	HEMO‐TAA)	
or	only	water	without	TAA	(CTL‐H2O	and	HEMO‐H2O).	TAA	(pur‐
chased	 as	 white	 crystalline	 powder	 from	 Sigma‐Aldrich;	 St	 Louis,	






istered.	 After	 25	weeks,	 the	mice	 were	 sacrificed	 and	 their	 livers	
harvested.	Three	haemophilia	mice	died	unexpectedly	before	Week	
25	 due	 to	 external	 haemorrhages	 (two	 in	 the	HEMO‐H2O	 group;	
one	in	the	HEMO‐TAA	group)	and	were	excluded	from	analysis.
At	 the	 time	 of	 harvest,	 liver	 sections	were	 fixed	 in	 formalin	 and	
embedded	 in	 paraffin.	 Slices	were	 stained	with	PicroSirius	Red	 then	
